Aug. 13, 2025 — BioCardia, Inc., a provider of cellular and cell-derived therapeutics for treating cardiovascular and pulmonary diseases, and CART-Tech, B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions, have announced they have entered into an exclusive development and commercialization agreement for Heart3D Fusion Imaging. The Heart3D system is expected to enhance two-dimensional x-ray images used for cardiac biotherapeutic delivery and biopsy procedures by fusing these images with annotated pre-procedure three-dimensional anatomical heart models created from gold standard MRI and CT images.
Under the development and commercialization partnership, the parties are advancing Heart3D Fusion Imaging for biotherapeutic interventions and cardiac biopsy. The system is expected to be sold initially as a research tool with support services for partners in preclinical studies and subsequently approved for standard clinical practice. This partnership leverages the parties’ clinical experience in positioning electrodes and drug delivery systems in the heart and their complimentary intellectual property portfolios for cardiac fusion imaging. BioCardia will have exclusive distribution rights for biotherapeutic delivery world-wide and for cardiac biopsy in the United States. All other distribution rights remain with CART-Tech.
“Heart3D Fusion Imaging has potential to enhance the procedural experience for interventional cardiologists, improve therapeutic strategies for sponsors and most importantly, benefit patients,” said Peter Altman, BioCardia CEO. “This is a significant opportunity for both firms, as management estimates that a single approved biologic therapy for a large market cardiology indication could potentially generate $100 million of revenue annually from Heart3D automated cloud-based image post-processing and live procedural guidance services if it becomes standard of care. The BioCardia team is looking forward to doing great things with the world class CART-Tech team.”
“Together, we present the ultimate biotherapeutic delivery solution for partners developing cell, gene, and protein-based therapies to the heart,” said Johan Maas, CART-Tech CEO. “The Heart3D Fusion Imaging product offering has potential to significantly enhance procedural planning and real time image precision for the delivery of biologic agents. Our mission is to help advance these therapies for the patients suffering from cardiovascular disease.”
As part of the partnership, BioCardia has licensed global exclusive rights to CART-Tech intellectual property for the fields of biotherapeutic intervention. CART-Tech has licensed global exclusive rights to BioCardia intellectual property for cardiac resynchronization therapy.
For more information, go to: https://www.biocardia.com/pipeline/heart3d-fusion-imaging/id/5011
November 13, 2025 
